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Abstract
Background: Qing’e formula (QEF), prepared from an ancient Chinese recipe, was previously suggested to regulate
bone metabolism and improve bone mineral density in patients with osteoporosis. To study the effects of
medicated serum containing QEF on the in vitro differentiation of bone marrow-derived mesenchymal stem cells
(BMSCs) isolated from the proximal femurs of postmenopausal osteoporosis (PMOP) mice.
Methods: Using an established mouse model of PMOP, mononuclear cells were isolated from the bone marrow
present in the proximal femurs and cultured. PMOP mice were also randomly divided into four groups: the
untreated group (Group A) and the groups treated with respectively low (Group B), medium (Group C), and high
(Group D) concentrations of QEF. Serum was isolated from each and used to treat the cultured BMSCs in
conjunction with recombinant human bone morphogenetic protein-2 (rhBMP-2). Cell morphology, proliferation
rates, intracellular alkaline phosphatase (ALP) activity, and transforming growth factor-beta 1 (TGF-β1) mRNA
expression were evaluated.
Results: QEF-treated serum, particularly that containing moderate and high concentrations, appears to enhance the
rhBMP-2-mediated changes in cell morphology, proliferation, and differentiation (determined via the expression of
TGF-β1 mRNA and ALP activity) observed in the BMSCs isolated from PMOP mice.
Conclusions: QEF may play a role in the prevention and treatment of PMOP by enhancing the activity of rhBMP-2.
Keywords: Osteoporosis, Bone marrow-derived mesenchymal stem cells, Qing’e formula, Transforming growth
factor β
Background
Postmenopausal osteoporosis (PMOP) is one of the major
diseases seriously affecting female health worldwide.
PMOP is categorized as a kind of bone atrophy disease
affecting, as the name suggests, postmenopausal women.
The current understanding of how to treat this disease is
largely limited. Notably, some success in the prevention
and treatment of PMOP has been observed using a trad-
itional Chinese medicine (TCM) known as Qing’e formula
(QEF). QEF consists of four primary compounds: cortex
eucommiae, fructus psoraleae, semen juglandis, and Al-
lium sativum. These ingredients are blended in a specific
ratio and the resulting mixture has been used in TCM
since the Song Dynasty (10th century CE) to invigorate
the kidneys, replenish bone and muscle tissue, slim the
body, and improve complexion. QEF is also commonly
used clinically as an oestrogen agonist for the treatment of
osteoporosis, particularly in PMOP [1].
Furthermore, our previous research has shown that by
adjusting the mRNA expression of vitamin D3 receptor
(VDR), QEF is capable of activating bone metabolism to
prohibit further loss of bone mass, thereby preventing the
bone deterioration observed to occur during osteoporosis
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[2]. Notably, VDR has been shown to regulate a number
of downstream target genes important in mineral metab-
olism as well as many essential genes involved in osteo-
blast function [3]. For example, transforming growth
factor-beta 1 (TGF-β1) is locally produced by osteoblasts
and plays an important role as a “coupling factor” in bone
remodelling. The link between VDR and TGF-β1 was
discovered in a study by Takeshita et al. [4] in which they
demonstrate a synergistic effect between 1-alpha, 25-
dehydroxy-vitamin D3 (i.e., a VDR-dependent mechanism)
and TGF-β1 on the transcriptional activation of activation
protein-1 (AP-1), a known regulatory factor in bone me-
tabolism. Although it is possible that QEF functions via a
similar signalling cascade, the underlying mechanism be-
tween QEF and VDR, or any of these other osteoporosis-
related genes, during PMOP is largely unknown.
With the rapid development of various molecular biol-
ogy techniques, our understanding of bone atrophy-
related diseases, including PMOP, has greatly expanded.
In fact, recent studies suggest that the differentiation and
regulation of bone marrow-derived mesenchymal stem
cells (BMSCs) play an important role in osteoporosis pre-
vention and treatment. Thus, in this study, we have
utilized serum isolated from QEF-treated PMOP mice to
explore the effects of QEF on the osteogenic differenti-
ation of BMSCs isolated from the proximal femurs of
PMOP mice. In doing so, we sought to elucidate the fun-
damental cellular and molecular mechanisms of PMOP
and uncover the possible clinical applications of QEF.
Methods
Main instruments and reagents
The following instruments were used in this study: flow cyt-
ometer (Becton-Dickinson, USA), double-sided ultraclean
workbench (China), carbon dioxide incubator (Sheldon,
USA), inverted phase contrast microscope (Olympus,
Japan), and a UV spectrophotometer, (Tianjin TianGuang
Optical Instruments Co., LTD.). The primary reagents used
in the following experimental procedures were: LG-DMEM
powdered medium (Gibco, USA), fetal bovine serum
(Gibco, USA), trypsin powder (Sigma, USA), alkaline
phosphatase (ALP) assay kit (Shanghai Hongqiao Medical
Reagent Research Institute), β-glycerol sodium phosphate
(Sigma, USA), and recombinant human bone morpho-
genetic protein 2 (rhBMP-2) (R&D, USA).
Preparation of QEF
Four kinds of herbal QEF were purchased from the
Pharmacy of Union Hospital at Tongji Medical College of
Huazhong University of Science and Technology (HUST).
The main ingredients of QEF, which include cortex
eucommiae (960 g), fructus psoraleae (480 g), semen
juglandis (300 g), and Allium sativum (240 g), were
washed and placed in a multifunctional extractor (Table 1).
All four herbs were identified and authenticated by Prof.
Jiancai Wu (The Botany and Drug Department of Union
Hospital at Tongji Medical College of HUST). The herbs
were immersed in five-fold their volume of regular water
for 2 h, followed by boiling for 2 h. After filtering the boiled
decoction, the herbal residues were repeatedly boiled twice
for 1 h each time, and the resulting boiled decoction was
filtered, combined with the first filtrate, and condensed to a
thick paste. This paste was then added to a three-fold vol-
ume of 95 % ethanol while stirring. After standing for 24 h,
the solution was filtered to recover the ethanol fraction,
which was then concentrated to a decoction of 5 g/mL [5].
Preparation of serum containing QEF
Female C57BL/6 mice were purchased from and main-
tained at the Experimental Animal Center of HUST,
Wuhan, China (certificate: NO. 0237269; Hubei provin-
cial experimental animal facility permit: SYXK [Hubei]
2010-0057). Disinfected food and water were provided
under sterile conditions.
A mouse model of PMOP was established for experi-
mental use by Thompson et al. [6]. Briefly, the animals
used in this study were anaesthetised with an intraperi-
toneal injection of 1 % pentobarbital sodium (30 mg/kg
body weight (b.w.)) and maintained in a prone position.
Ovariectomy was performed via a midline dorsal incision
under sterile conditions after which both ovaries were
identified adjacent to the inferior pole of the kidneys in
the peritoneal cavity, the blood vessels were tied off
using No. 4 sutures, and both ovaries were removed.
The layers of tissue were then closed and sutured. Start-
ing from post-operative day 5, a pap smear (once/day)
was taken from each animal for 5 consecutive days. A
successful bilateral ovariectomy was confirmed by the
absence of keratosis in these pap smear screenings. Sam-
ples exhibiting keratosis were discarded. Animals were
fed and allowed to move ad libitum for 12 weeks [6].
The ovariectomised mice were randomized into four
groups (n = 10 for each): group A (blank control group
treated with 2 ml of distilled water); group B (low concen-
tration group treated with 0.85 g/kg b.w. QEF), group C
(medium concentration group treated with 1.7 g/kg b.w.
QEF), and group D (high concentration group treated with
3.4 g/kg b.w. QEF). Further, the mice in each group re-
ceived a daily intragastric dose of the designated treatment
Table 1 Components of modified QEF and total dose of each
herb
No. herbal name Processing Contents (g)
1 cortex eucommiae steep in wine 960
2 fructus psoraleae fried, peeled and dipped in ginger 480
3 semen juglandis peeled 300
4 Allium sativum steaming 240
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(water or various concentrations of QEF) via gavage for
3 days. The medium dose of QEF was calculated in
accordance with the guidelines correlating dose
equivalents between humans and laboratory animals,
which is based on the ratio of the animal’s body sur-
face area [7]. Blood samples were collected 2 h after
the final administration.
Serum was then isolated from each blood sample, and
heat inactivation was conducted at 56 °C for 30 min. After
filtration and repackaging, these “medicated serum” sam-
ples were stored at −80 °C for future use. Notably, all ex-
periments were performed in accordance with HUST’s
ethical guidelines for animal care as well as the guidelines
set by the World Health Organization, and the experimen-
tal protocols were all approved by the animal care
committee of HUST.
Isolation, cultivation, and identification of BMSCs
Bone marrow (4–5 ml) was isolated from untreated
PMOP mice and placed into a 20 ml sterile centrifuge
tube containing Dulbecco’s modified Eagle’s medium
(DMEM). Percoll (1.073 g/ml) was used to separate the
mononuclear cell fraction using density gradient centri-
fugation. After several rounds of washing, the mono-
nuclear cells were re-suspended in DMEM containing
10 % fetal bovine serum, and incubated at 37 °C with
5 % CO2. The medium was changed every 3–5 days, and
non-adherent cells were removed in order to obtain cells
with the known characteristics of adherent BMSCs. Cell
morphology, adherence, and cellular growth were ob-
served every day. After cell confluence was 80–90 %,
0.25 % trypsin (containing 0.02 % EDTA) was used to
passage the cells. The trypsinized cells were then inocu-
lated into new 25 mL culture flasks at a density of 5,000
per cm2 and incubated. The culture medium was chan-
ged in these flasks once every 2 to 3 days. These cells
were marked as P1 (the first generation). The passaging
procedure outlined above was repeated each time the
cells reached 80–90 % confluency. Further, when the P3
cells achieved 90 % confluency, the culture media was
removed from each flask and the cells were thoroughly
washed twice using phosphate buffered saline (PBS).
After washing, aliquots of the cells (1 × 106 cells) were
incubated in fluorescence-activated cell sorting (FACS)
buffer containing monoclonal antibodies against CD34,
CD90, CD44, CD45, or an appropriate isotype control
antibody (all obtained from Boshide, China). After
30 min in the dark on ice, cells were washed again in
FACS buffer. Then, the expression of CD34, CD90,
CD44, and CD45 antigens were detected via flow cyto-
metric analysis using CellQuest software. Cells were
gated on forward and side scatter to exclude debris and
aggregates, and dead cells were excluded using 7-
Amino-Actinomycin D (Boshide, China) staining.
BMSC treatment and morphological observation
Serum isolated from mice in the four experimental groups
was added to separate culture wells, each of which also
contained recombinant human bone morphogenetic
protein-2 (rhBMP-2, 150 ng/mL). Third generation
BMSCs were collected and the cell density was adjusted
to 1 × 105/ml. For each group, 20 μl of the cell suspension
was added and incubated at 37 °C with 5 % CO2. Accord-
ing to results from preliminary experiments, no cytotox-
icity was detected when the concentration of animal
serum in the culture medium was below 20 % [8]. There-
fore, in this study, animal serum isolated from each group
was diluted to a concentration of 10 % in DMEM prior to
further use. Morphological changes in the BMSCs for each
group were observed using an inverted phase contrast
microscope.
Determination of relative cell number and cell
proliferation levels
Cell proliferation was determined for the BMSCs in each
of the four treatment groups using the MTT method on
days 1, 3, 5, 7, 10, 12, 15, and 20. To each well, 20 μl of
MTT solution (5 mg/mL) was added and incubated for
4 h at 37 °C before the reaction was terminated. The su-
pernatants were then carefully aspirated off each well.
DMSO (150 μl) was added and cells were lysed after 10 s
of oscillation, which fully dissolved the crystals. Optical
density (OD) values were determined with a spectropho-
tometer at a wavelength of 490 nm.
Detection of ALP activity
On days 5, 10, 15, and 20, the cultured cells of each
treatment group were washed twice with PBS, and
0.25 % trypsin was used to digest the cells. This trypsini-
sation was followed by the addition of 1 ml of culture
medium to terminate the digestion. After centrifugal
washing, cell lysis solution was added, and ALP activity
was assayed according to the kit manufacturer’s instruc-
tions. OD was measured with a spectrophotometer at a
wavelength of 520 nm and ALP activity was calculated.
Determination of TGF-β1 mRNA expression
Total RNA was extracted from three unique cultures of
each of the four treatment groups using TRIzol protocol.
The isolated mRNA was reverse transcribed using the
following reaction mixture: 9 μL of H2O, 1.0 μL of oligo
(dT15), 2.0 μL of template, 4.0 μL of 5× reaction buffer,
2.0 μL of 10 mM dNTPs, 1.0 μL of RNA inhibitor, and
1.0 μL of reverse transcriptase. The following reaction
conditions were used: 42 °C for 30 min and 80 °C for
5 min. Using the subsequent cDNA from each sample,
TGF-β1 mRNA expression was then assessed using quan-
titative RT-PCR with FastStart Universal SYBR Green 1
PCR master mix (Rox, Roche, USA) in an ABI7300
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real-time PCR system (Invitrogen, China). The following
forward (F) and reverse (R) primers were used: β-actin (F:
TCACCCACACTGTGCCCATCTACGA, R: TCACCCA
CACTGTGCCCATCTACGA); and TGF-β1 (F: GTGC
TCGCTTTGTACAACAGC, R: TTACCAAGGTAACGC
CAGG). The amount of TGF-β1 mRNA was normalized
to that of β-actin mRNA. The quantitative PCR reaction
mixture contained 1.0 μL of cDNA, 5.0 μL of 10× reaction
buffer, 7.0 μL of 25 mmol/L MgCl2, 1.0 μL of 10 mmol/L
dNTPs, 0.8 μL of forward primers (20 pmol/μL), 0.8 μL of
reverse primers (20 pmol/μL), 1.0 μL of SYBR Green, and
0.5 μL of Taq polymerase (5 U/μL). The cycling conditions
were as follows: 95 °C for 10 min, followed by 40 cycles of
95–60 °C for 15 s, and 60 °C for 5 min. Finally, the Ct
values were calculated using the ΔΔCt method and ana-
lysed as previously described [9].
Statistical analysis
All data are presented as the mean ± standard deviation
(SD). Statistical analyses were performed using the
Kruskal-Wallis test or an analysis of variance (ANOVA)
followed by the least significance difference test (Student’s
t-test) for multiple comparisons using SPSS software
(version 13.0, SPSS, Inc., Chicago, IL, USA). A P value less
than 0.05 was considered statistically significant.
Results
Identification of BMSCs
Using flow cytometry, the main negative BMSC surface
markers CD34 and CD45 were confirmed to be negative
in our cell cultures, being expressed in only 1.29 and
2.51 % of the cells, respectively (Fig. 1a and b). On the
other hand, the cultured BMSCs were observed to ex-
press the main positive markers CD44 and CD90 on the
cell surface, being present on the surfaces of 90.18 and
92.63 % of the cells, respectively (Fig. 1c and d). Notably,
when culturing cells isolated directly from a tissue, it
can often be difficult to prevent the contamination of
other cell types, particularly after continued passaging.
These higher percentages (more than 90 %), indicate
Fig. 1 Identification of BMSCs. Flow cytometric detection data showing little to no expression of the negative cell markers CD34 (a) and CD45 (b)
as well as the positive expression of the BMSCs markers CD44 (c) and CD90 (d). FITC fluorescein isothiocyanate, FSC-H forward scatter-hight
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that our BMSC cultures primarily contained this specific
cell type and contamination from other mononuclear
cells was low.
BMSC growth and morphology following the addition of
QEF-treated serum
Although the number of cells increased in all four treat-
ment groups, the level of cellular proliferation in groups
A and B, as determined by the change in the number of
adhesive cells, was distinctly slower than that observed
for groups C and D (Fig. 2a). Further, there was no sig-
nificant difference between groups A and B in terms of
the relative number of cells (P > 0.05), while the number
of cells in groups C and D were significantly higher than
those of groups A and B from day 5 onward (P < 0.05).
Cellular growth in groups A, B, and C peaked on day 10
before entering the plateau phase, while that of group D
reached a peak value on day 11.
Moreover, the morphology of the cells in groups A
and B also appeared to be different compared to that of
groups C and D. For example, after composite cultiva-
tion for 4 h, cell adhesion was observed for groups C
and D, and the cells appeared to be oval or round in
morphology, while less cells adhesion was apparent in
groups A and B at this time. Furthermore, after one day
in culture, the proliferating cells in groups C and D were
uniformly distributed and spindle-shaped. On day 3, as
the number of cells increased in each group, the cells in
groups C and D appeared to be polygonal or spindle-
shaped, unlike the cells of groups A and B. As the cells
continued to proliferate from day 5 to 10, the cells in
groups C and D clearly occupied the flask with a mono-
layer of morphologically similar cells (Fig. 2b–e).
Effect of QEF-treated serum on ALP activity and TGF-β1
mRNA expression in cultured BMSCs
Over time, the cellular ALP activity in the cultured
BMSCs gradually increased in each treatment group until
day 15 (Fig. 3). Notably, the cellular ALP activity in group
B was not significantly different from that of the control
(group A) at any time point, while the activities observed
for groups C and D were significantly higher (P < 0.05).
This was particularly evident after day 15, when the cellu-
lar ALP activity of groups A and B appeared to gradually
slow down, while those of groups C and D continued to
increase.
In addition to monitoring ALP activity, the relative ex-
pression of TGF-β1, another marker of osteoblast mes-
enchymal cell differentiation, was also evaluated 20 days
after QEF-treated serum was introduced to the cultured
BMSCs (Fig. 4). The relative TGF-β1 mRNA expression
levels observed for groups C (6.23 ± 1.21) and D (5.03 ±
1.01) were significantly higher than those of the control
group A (1.00 ± 0.16, P < 0.05), while the expression in
group B (1.21 ± 0.18) was not significantly different from
group A (P > 0.05).
Discussion
In the present study, we have utilized primary in vitro cul-
ture of BMSCs isolated from mice with induced PMOP in
order to investigate the possible clinical application of QEF
for the treatment of this disease. It is has been well docu-
mented that after menopause, bone resorption occurs at a
faster rate than bone deposition/growth, causing a gradual
Fig. 2 Proliferation and morphology of cultured BMSCs after
treatment with QEF-containing serum. The level of cellular proliferation,
determined by counting the number of cells, was visually monitored in
cells cultured in serum treated with water (control, group A); a low
concentration of QEF (group B); a medium concentration of QEF
(group C); and a high concentration of QEF (group D). During
this time, there was no significant difference observed between
groups A and B (P > 0.05), while groups C and D were significantly
higher than A and B from day 5 onward (P < 0.05) (a). Values are
expressed as the mean ± SD; ★P < 0.05 compared to group A at the
specified time point, ▲P < 0.05 compared to group B at the specified
time point. All groups reached a growth plateau between culture
day 10 and 11. Representative images of the cellular morphology
at day 10 are shown for group A (b), group B (c), group C (d),
and group D (e). All photomicrograph images were obtained at
a ×100 magnification
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weakening of the bone. This can result in an increased
occurrence of bone fracturing and a significantly altered
quality of life for the patient. Although the specific mechan-
ism underlying PMOP is unknown, a number of treatment
options have been explored. For example, in osteoporosis
and osteonecrosis patients, QEF treatment was shown to
elevate the levels of serum matrix metalloproteinase-2,
bone ALP, osteocalcin, cross-linked C-telopeptide of type I
collagen, and urinary cross-linked N-telopeptide of type I
collagen [2, 10]. These data indicate that QEF could poten-
tially enhance osteoblastic activity, promote bone forma-
tion, inhibit bone resorption, and increase bone mass and
quality. However, the mechanism underlying these changes
or even the specific cell type(s) affected in the bone was
previously unexplored. To our knowledge, this is the first
published report describing the effects of QEF on the
growth and morphology of BMSCs isolated from PMOP-
induced mice.
BMSCs are known to differentiate into various types
of cells, including osteoblasts, fibroblasts, chondroblasts,
and adipocytes [11]. Further, spontaneous in vitro differ-
entiation of BMSCs into stable osteoprogenitor cells is
largely dependent on the culture conditions [11–15].
Therefore, optimal in vitro conditions are of great im-
portance when studying the formation of bone tissues
[16–18]. These primary BMSC cultures have also been
used to investigate the cellular changes that occur in
response to experimental treatment of a bone disease,
including osteoporosis [19]. Notably, in almost all exper-
iments utilizing primary BMSC cultures, including the
current study, cellular differentiation was induced using
one or more BMPs. BMPs are glycoprotein polypeptides
that are innately expressed in the bone matrix. The
members of this protein family all have similar struc-
tures and functions (with the exception of BMP-1), con-
tain a disulfide bond, and have a molecular weight
between 18 and 30 kDa [20]. Although they function in
a similar manner to induce osteogenic mesenchymal cell
differentiation into cartilage and bone, the ability of each
BMP to do so greatly varies. It appears that BMP-2 has
the strongest osteogenic capability and is a crucial regu-
lator of bone tissue formation in the human body [21].
Therefore, this BMP has been widely studied and used
during in vitro BMSC culture experiments [22].
Notably, in preliminary experiments, QEF-containing
serum did not have any significant effects on the func-
tion of BMSCs isolated from PMOP mice when used
without rhBMP-2 (data not shown). Thus, we chose to
focus on the synergistic effects mediated by QEF in
rhBMP-2-induced BMSCs isolated from the proximal fe-
murs of PMOP mice. Using these BMP-induced cell cul-
tures, we have shown that in the first 10 days following
treatment with QEF-treated serum, the cells treated with
moderate (group C) and high (group D) concentrations
Fig. 3 ALP activity assay. Cellular ALP activity was monitored in cells
cultured in serum treated with water (control, group A); a low
concentration of QEF (group B); a medium concentration of QEF
(group C); and a high concentration of QEF (group D). Activity
appears to gradually increase in each group for the first 15 days in
culture, with the ALP in groups C and D being significantly (P < 0.05)
more active than that of groups A. This difference is even more
evident from day 15 to day 20, as the ALP activity in groups A and B
decreased slightly while that of C and D remained high. The values
are expressed as means ± SD; ★P < 0.05 compared to group A at the
specified time point
Fig. 4 TGF-β1 mRNA expression. The relative expression of TGF-β1
mRNA was evaluated in cultured BMSCs 20 days after the
introduction of serum treated with water (control, group A); a low
concentration of QEF (group B); a medium concentration of QEF
(group C); and a high concentration of QEF (group D). The
expression observed in group B (1.21 ± 0.18) was not significantly
different from group A (1.00 ± 0.16, P > 0.05), while the expression in
groups C and D (6.23 ± 1.21 and 5.03 ± 1.01, respectively) were
significantly higher than those of group A (P < 0.05). Values are
expressed as the mean fold change ± SD, with the control group
being set to 1; ★P < 0.05 compared to group A
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of QEF grew exponentially, while cells from the un-
treated controls (group A) and low concentration groups
(group B) displayed slower growth. Further, from day 10
to day 20, the growth became completely stagnant in the
control, low concentration, and moderate concentration
groups, while the cells in the high concentration group
still appeared to grow, although at a lower rate com-
pared to earlier time points. Further, cells cultured in
QEF-treated serum were also more adhesive and dis-
played morphological characteristics of healthy differen-
tiated osteoblastic cells, indicating that the moderate
and high concentrations of QEF exhibit a significant ef-
fect on BMSCs condition during PMOP.
In order to further determine the effects of QEF on
BMSCs of PMOP mice, an ALP activity assay was con-
ducted. ALP, a zymoprotein secreted by osteoblasts, is
highly specific and its expression level in osteoblasts can
reasonably reflect the degree of differentiation and func-
tional status of the cell [23]. The results of this analysis
show that, within 15 days, ALP activity in the groups
treated with moderate and high concentrations of QEF
was rapidly increased, while that observed for the low
concentration and control groups was only marginally in-
creased. Further, after this first 15 days in culture, the ALP
activity in the low concentration and moderate concentra-
tion groups as well as the control group stopped increas-
ing altogether, while that of the high QEF concentration
group still appeared to increase slowly. These results dem-
onstrate that the cellular ALP secretion lagged behind cel-
lular growth and differentiation and that a higher
concentration of ALP was secreted after the mature cell
was formed.
Furthermore, the expression of TGF-β1 mRNA was
used as an additional marker of cellular differentiation.
TGF-β1 is widely expressed in normal tissues and is par-
ticularly abundant in bone [24]. Indeed, a large number
of studies have shown that TGF-β plays a pivotal role in
bone regeneration and is involved in the formation and
growth of bone during embryogenesis [25]. During the
early stages of bone formation in newborns, TGF-β1 and
TGF-β2 in particular are expressed in the cartilage and
periosteum, and TGF-β1 has been shown to promote
the proliferation and differentiation of mesenchymal
cells into mature bone cells in these tissues [26]. Mech-
anistically, TGF-β1 mainly functions to regulate the tran-
scription and activity of genes essential for mesenchymal
cell differentiation in addition to promoting the synthe-
sis of extracellular matrix (ECM) and ECM associated
proteins (e.g., collagen, osteonectin, and osteopontin)
and increasing the rate of bone matrix deposition [27].
TGF-β1 expression also influences the directional migra-
tion of osteoblasts, which is essential for the chemotactic
movement of these cells towards the site of active bone
resorption [28]. Notably, other in vitro studies have shown
that a kidney-invigorating (Bushen) decoction used in
TCM can enhance the expression of TGF-β1 in the cyto-
plasm and plasma membrane of osteoblasts [29, 30]. Here,
our data demonstrate that rhBMP-2 alone (control group)
can induce TGF-β1 expression, indicating BMSC differen-
tiation. We also observed that this TGF-β1 expression was
further promoted in QEF-treated cells, with the maximum
effect being found for the cells cultured in serum treated
with moderate and high concentrations of QEF.
Finally, it is important to note that there are several lim-
itations to this study. First, the preparation and application
of QEF-containing serum in this study are still at the
exploration stage as there are no unified standards to fol-
low in the current literature. Effective compounds used in
TCM are largely underused in the majority of modern
studies, making their optimization during in vitro analyses
more difficult and time consuming. Second, the effects of
rhBMP-2 and QEF on BMSCs isolated from normal, non-
PMOP mice were not studied in the current investigation.
However, we believe the side-effects of QEF on non-
PMOP cells would be limited, particularly at the serum
concentration utilized. Third, only a limited number of
relevant indicators are included in this study, including
ALP activity and TGF-β1 mRNA expression. Additional
work using other indicators is necessary to further explore
the cellular mechanisms involved in PMOP and the effects
of QEF treatment.
Conclusions
Taken together, this study is the first effort to determine
the possible clinical application of QEF to treat PMOP.
These experiments highlight the use of rhBMP-2 to
induce the passage and differentiation of BMSCs isolated
from the proximal femurs of PMOP mice into osteoblast-
like cells. In addition, this process appears to be further
promoted by culturing the cells in medicated serum
isolated from PMOP mice treated with varying concentra-
tions of QEF in a dose-dependent manner. While this
study provides a secure foundation, additional work is
warranted in order to fully understand the role of this
TCM in osteoporotic BMSC differentiation.
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